Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19

A Randomized, Double-blind, Placebo-controlled, Phase Ia/IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years

This study is a randomized, double-blinded, and placebo-controlled phase Ia/IIa clinical trial of the Inactivated SARS-CoV-2 Vaccine to evaluate the safety and immunogenicity of the vaccine in healthy people aged 18~59 Years.

Study Overview

• Status: Completed
• Conditions: COVID-19
• Intervention / Treatment: Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule; Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule; Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule; Biological: Placebo on a 0- and 28-day schedule; Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule; Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule; Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule; Biological: Placebo on a 0- and 14-day schedule

Detailed Description

This phase Ia/IIa trial is designed to evaluate the safety and immunogenicity of different doses of the Inactivated SARS-CoV-2 Vaccine inoculated with different immunization schedules based upon the randomized, double-blind and placebo-controlled principle. A total of 942 subjects aged 18 to 59 years old will be enrolled in the study, of which 192 and 750 will be enrolled for phase Ia and phase Ⅱa,respectively.The enrolled subjects in phase Ia receive two doses of low-, medium-, or high-dose of experimental vaccines or placebo at an interval of 14 or 28 days, while the enrolled subjects in Phase Ⅱa receive two doses of medium, high-dose experimental vaccines or placebo at an interval of 14 or 28 days.

• Study Type: Interventional
• Enrollment (Actual): 942
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Qihan Li, PhD; Phone Number: 86-0871-68335905; Email: liqihan@imbcams.com
• Study Contact Backup: Name: Yanchun Che, Researcher; Phone Number: 86-0871-68335905; Email: cheyanchun@imbcams.com

Study Locations

• China
  • Sichuan
    • Chengdu, Sichuan, China, 610041
      • West China Second University Hospital, Sichuan University / West China women's and children's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 59 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Phase Ia:

  1. Healthy adults aged 18 to 59 years (including boundary values), both men and women.
  2. Proven legal identity.
  3. Participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
  4. Participants should be able to communicate well with investigators, understand and comply with the requirements of this trial.
  5. Axillary temperature ≤37.0 ℃.

• Phase IIa:

  1. Healthy adults aged 18 to 59 years (including boundary values), both men and women.
  2. Proven legal identity.
  3. Participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required.
  4. Participants should be able to communicate well with investigators, understand and comply with the requirements of this trial.
  5. Axillary temperature ≤37.0 ℃.

Exclusion Criteria:

• Phase Ia:

  1. Contraindications for vaccination.
  2. History of allergy to vaccines or drugs.
  3. Immunization with any vaccine within 1 month.
  4. History of abnormal clinical manifestations and serious diseases to be excluded, including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bones and other system diseases, and a history of malignant tumors.
  5. Those who developed acute disease within 2 weeks, or had symptoms of fever or upper respiratory tract infection within 7 days.
  6. Those who have a hereditary bleeding tendency or coagulation dysfunction, or a history of thrombosis or bleeding disorders.
  7. Those who cannot tolerate venipuncture, or have a history of halo needles or halo blood.
  8. Surgical removal of spleen or other important organs for any reason.
  9. Those who have undergone surgery within 3 months before signing the informed consent, or those who plan to perform surgery during the trial or within 3 months after the end of the trial (including cosmetic surgery, dental and oral surgery).
  10. Those who donated or lost blood (≥400 mL) in the past 3 months, who received blood transfusion or use of blood products, or who planned blood donation during the trial.
  11. Receipt of other investigational or unregistered products (drugs, vaccines, biological product or devices) in the past 3 months, or plan to use other investigational or unregistered products during the study.
  12. Receipt of immunosuppressive therapy within 6 months before signing the informed consent form, such as long-term systemic glucocorticoid therapy (with systemic glucocorticoid therapy for more than 2 weeks within 6 months, such as prednisone or similar drugs) ), but local administration (such as ointment, eye drops, inhalation, or nasal spray) is allowed. The local administration should not exceed the dosage recommended in the instructions or have any signs of systemic exposure.
  13. Those who have took soft drugs (such as marijuana) within 3 months before signing the informed consent form or took hard drugs (such as: cocaine, phencyclidine, etc.) within 1 year before the trial.
  14. Those who smoked more than 5 cigarettes per day within 3 months before signing the informed consent form.
  15. The weekly drinking volume is greater than 14 units within 3 months before signing the informed consent form (1 unit alcohol approximately equal to 360 mL beer or 45 mL spirits with 40% alcohol content or 150 mL wine).
  16. The comprehensive physical examination does not meet the health standards, mainly including: (1) Those with abnormal vital signs with clinical significance. (2) BMI<18 kg/m^2 or> 30 kg/m^2. (3) Abnormal laboratory examination with clinical significance. (4) Those who tested positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis B e antigen, hepatitis C virus antibody, or Treponema pallidum antibody (tp-trust).
  17. Participants who have a positive pregnancy test, or are breastfeeding, or plan to become pregnant, or plan to donate sperm or eggs from the screening to 12 months after the second vaccination.
  18. Positive in drug abuse screening during the screening period (Morphine, Methamphetamine, Ketamine, MDMA and Tetrahydrocannabinolic acid).
  19. Positive in alcohol breath test during the screening period.
  20. Positive in SARS-CoV-2 nucleic acid screening or antibodies (IgG or IgM) screening.
  21. History of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS) or other coronavirus infection (HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1).
  22. History of contact with confirmed or suspected cases infected with SARS-CoV-2 within 1 month.
  23. Any other situations judged by investigators as not suitable for participating in this study.

• Phase IIa:

  1. Contraindications for vaccination.
  2. History of allergy to vaccines or drugs.
  3. Immunization with any vaccine within 1 month.
  4. History of abnormal clinical manifestations and serious diseases to be excluded, including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bones and other system diseases, and a history of malignant tumors.
  5. Those who developed acute disease within 2 weeks, or had symptoms of fever or upper respiratory tract infection within 7 days.
  6. Those who have a hereditary bleeding tendency or coagulation dysfunction, or a history of thrombosis or bleeding disorders.
  7. Surgical removal of spleen or other important organs for any reason.
  8. Those who have undergone surgery within 3 months before signing the informed consent, or those who plan to perform surgery during the trial or within 3 months after the end of the trial (including cosmetic surgery, dental and oral surgery).
  9. Those who donated or lost blood (≥400 mL) in the past 3 months, who received blood transfusion or use of blood products, or who planned blood donation during the trial.
  10. Receipt of other investigational or unregistered products (drugs, vaccines, biological product or devices) in the past 3 months, or plan to use other investigational or unregistered products during the study.
  11. Receipt of immunosuppressive therapy within 6 months before signing the informed consent form, such as long-term systemic glucocorticoid therapy (with systemic glucocorticoid therapy for more than 2 weeks within 6 months, such as prednisone or similar drugs) ), but local administration (such as ointment, eye drops, inhalation, or nasal spray) is allowed. The local administration should not exceed the dosage recommended in the instructions or have any signs of systemic exposure.
  12. The comprehensive physical examination does not meet the health standards, mainly including: (1) Those with abnormal vital signs (Pulse <55 beats per minute or> 100 beats per minute at rest, Systolic blood pressure ≥140mmHg or Diastolic blood pressure ≥90mmHg, breathing> 20 beats per minute or <12 beats per minute). (2) Those who tested positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis B e antigen, hepatitis C virus antibody, or Treponema pallidum antibody (tp-trust).
  13. Participants who have a positive pregnancy test, or are breastfeeding, or plan to become pregnant, or plan to donate sperm or eggs from the screening to 12 months after the second vaccination.
  14. Positive in SARS-CoV-2 nucleic acid screening or antibodies (IgG or IgM) screening.
  15. History of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS) or other coronavirus infection (HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1).
  16. History of contact with confirmed or suspected cases infected with SARS-CoV-2 within 1 month.
  17. Any other situations judged by investigators as not suitable for participating in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Low dosage vaccine on a 0- and 28-day schedule; Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28	Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule; Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
Experimental: Medium dosage vaccine on a 0- and 28-day schedule; Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28	Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule; Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
Experimental: High dosage vaccine on a 0- and 28-day schedule; Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 28	Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule; Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28
Placebo Comparator: Placebo on a 0- and 28-day schedule; Two doses of placebo at the vaccination schedule of day 0, 28	Biological: Placebo on a 0- and 28-day schedule; Two doses of placebo at the vaccination schedule of day 0,28
Experimental: Low dosage vaccine on a 0- and 14-day schedule; Two doses of low dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14	Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule; Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
Experimental: Medium dosage vaccine on a 0- and 14-day schedule; Two doses of medium dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14	Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule; Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
Experimental: High dosage vaccine on a 0- and 14-day schedule; Two doses of high dosage Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0, 14	Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule; Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14
Placebo Comparator: Placebo on a 0- and 14-day schedule; Two doses of placebo at the vaccination schedule of day 0, 14	Biological: Placebo on a 0- and 14-day schedule; Two doses of placebo at the vaccination schedule of day 0,14

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse reactions/events rate	Occurence of adverse reactions/events after vaccination	7 days after vaccination
Adverse reactions/events rate	Occurence of adverse reactions/events after vaccination	28 days after vaccination
Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)	Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,14	14 days after the second vaccination
Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)	Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,28	28 days after the second vaccination
Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)	Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,14	14 days after the second vaccination
Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)	Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,28	28 days after the second vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serious adverse events	Occurence of Serious adverse events after vaccination	12 months after the second vaccination
Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)	Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,14	7, 14 and 28 days after the second vaccination
Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)	Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,14	14 and 28 days after the second vaccination
Level of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)	Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,14	7, 14 and 28 days after the second vaccination
Level of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)	Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,14	14 and 28 days after the second vaccination
Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)	Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,28	7 and 28 days after the second vaccination
Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)	Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,28	28 days after the second vaccination
Level of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)	Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,28	7 and 28 days after the second vaccination
Level of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)	Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,28	28 days after the second vaccination
Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)	Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,14	14 days after the second vaccination
Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)	Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,14	14 days after the second vaccination
Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)	Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,28	28 days after the second vaccination
Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)	Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,28	28 days after the second vaccination

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Level of IgM antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule)	Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,14	7, 14 and 28 days after the second vaccination
Level of IgM antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule)	Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,14	14 and 28 days after the second vaccination
Level of anti-N protein antibodies Phase Ia (Day 0, 14 schedule)	Level of anti-N protein antibodies for the Phase Ia immunization schedule of day 0,14	7, 14 and 28 days after the second vaccination
Level of anti-N protein antibodies Phase IIa (Day 0, 14 schedule)	Level of anti-N protein antibodies for the Phase IIa immunization schedule of day 0,14	14 and 28 days after the second vaccination
Level of IgM antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule)	Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,28	7 and 28 days after the second vaccination
Level of IgM antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule)	Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,28	28 days after the second vaccination
Level of anti-N protein antibodies Phase Ia (Day 0, 28 schedule)	Level of anti-N protein antibodies for the Phase Ia immunization schedule of day 0,28	7 and 28 days after the second vaccination
Level of anti-N protein antibodies Phase IIa (Day 0, 28 schedule)	Level of anti-N protein antibodies for the Phase IIa immunization schedule of day 0,28	28 days after the second vaccination
Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (both schedules)	Level of neutralizing antibodies against SARS-CoV-2 in serum for both the Phase Ia immunization schedules	3, 6, 9 and 12 months after the second vaccination
Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (both schedules)	Level of neutralizing antibodies against SARS-CoV-2 in serum for both the Phase IIa immunization schedules	6 and 12 months after the second vaccination
Level of IgG antibodies against SARS-CoV-2 Phase Ia (both schedules)	Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for both the Phase Ia immunization schedules	3, 6, 9 and 12 months after the second vaccination
Level of IgG antibodies against SARS-CoV-2 Phase IIa (both schedules)	Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for both the Phase IIa immunization schedules	6 and 12 months after the second vaccination
Cellular immune responses Phase Ia (Day 0, 14 schedule)	Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase Ia immunization schedule of day 0,14	7, 14 and 28 days after the second vaccination
Cellular immune responses Phase IIa (Day 0, 14 schedule)	Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase IIa immunization schedule of day 0,14	14 and 28 days after the second vaccination
Cellular immune responses Phase Ia (Day 0, 28 schedule)	Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase Ia immunization schedule of day 0,28	7 and 28 days after the second vaccination
Cellular immune responses Phase IIa (Day 0, 28 schedule)	Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase IIa immunization schedule of day 0,28	28 days after the second vaccination

Collaborators and Investigators

• Sponsor: Institute of Medical Biology, Chinese Academy of Medical Sciences
• Collaborators: West China Second University Hospital; Yunnan Center for Disease Control and Prevention
• Investigators: Principal Investigator: Xiaoqiang Liu, Yunnan Center For Disease Control and Prevention; Principal Investigator: Qin Yu, West China Second University Hospital

Publications and helpful links

General Publications

• Pu J, Yu Q, Yin Z, Zhang Y, Li X, Yin Q, Chen H, Long R, Zhao Z, Mou T, Zhao H, Feng S, Xie Z, Wang L, He Z, Liao Y, Fan S, Jiang R, Wang J, Zhang L, Li J, Zheng H, Cui P, Jiang G, Guo L, Xu M, Yang H, Lu S, Wang X, Gao Y, Xu X, Cai L, Zhou J, Yu L, Chen Z, Hong C, Du D, Zhao H, Li Y, Ma K, Ma Y, Liu D, Yao S, Li C, Che Y, Liu L, Li Q. The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial. Vaccine. 2021 May 12;39(20):2746-2754. doi: 10.1016/j.vaccine.2021.04.006. Epub 2021 Apr 9.
• Che Y, Liu X, Pu Y, Zhou M, Zhao Z, Jiang R, Yin Z, Xu M, Yin Q, Wang J, Pu J, Zhao H, Zhang Y, Wang L, Jiang Y, Lei J, Zheng Y, Liao Y, Long R, Yu L, Cui P, Yang H, Zhang Y, Li J, Chen W, He Z, Ma K, Hong C, Li D, Jiang G, Liu D, Xu X, Fan S, Cheng C, Zhao H, Yang J, Li Y, Zou Y, Zhu Y, Zhou Y, Guo Y, Yang T, Chen H, Xie Z, Li C, Li Q. Randomized, Double-Blinded, Placebo-Controlled Phase 2 Trial of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in Healthy Adults. Clin Infect Dis. 2021 Dec 6;73(11):e3949-e3955. doi: 10.1093/cid/ciaa1703.

Study record dates

Study Major Dates

• Study Start (Actual): May 15, 2020
• Primary Completion (Actual): August 10, 2020
• Study Completion (Actual): August 31, 2021

Study Registration Dates

• First Submitted: May 21, 2020
• First Submitted That Met QC Criteria: June 1, 2020
• First Posted (Actual): June 2, 2020

Study Record Updates

• Last Update Posted (Actual): October 11, 2023
• Last Update Submitted That Met QC Criteria: October 8, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: 20200401

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No